← Who reports today · Health Care
How Abbott Laboratories (ABT) makes money: Q2 2026 revenue breakdown
US GAAP · $M · vs Q2 2025 · reported 07/16/2026
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company founded in Chicago with headquarters in Abbott Park, Illinois. · Wikipedia
More about the company
The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.
Key growth driver: Diagnostics — the fastest-growing revenue line: $3,092, +42% y/y. · by the Q2 2026 report
How does Abbott Laboratories make money?
Abbott Laboratories brought in $12.6 billion of revenue in Q2 2026, up 13.0% year over year. The largest source was Medical Devices: $5.86 billion, or 47% of the total, followed by Diagnostics ($3.09B, 25%) and Nutrition ($2.14B, 17%); other lines add the remaining 12%. Net income for the quarter was $928 million, down 47.8% year over year.
Revenue by source, Q2 2026
- Medical Devices$5.86B · 47% · +9.0%
- Diagnostics$3.09B · 25% · +42.3%
- Nutrition$2.14B · 17% · −3.1%
- Established Pharmaceuticals$1.50B · 12% · +8.4%
Shares of $12.6B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.
When is ABT’s next earnings date?
Wednesday, October 21, 2026confirmed · before market open
Abbott Laboratories (ABT) is scheduled to report results for the quarter ending Sep 2026 on Oct 21, 2026. Consensus EPS forecast: $1.43 (8 analysts), vs $1.30 in the same quarter last year.
What time does ABT report? Usually before market open: the last 4 results releases reached the SEC at 7:36 am, 7:36 am, 7:35 am, 7:33 am ET.
Last report: Jul 16, 2026 (Q2 2026) — broken down in the Sankey chart below. Dates and consensus: Nasdaq / Zacks Investment Research; companies do reschedule. Who else reports this week →
All figures in $M.
Revenue
$12,593
+13.0%
Gross profit
$6,610
+5.4%
52.5% margin
Operating income
$1,693
−17.5%
13.4% margin
Net income
$928
−47.8%
$0.53 diluted EPS
Verdict: reported sales jumped 13% on the Exact Sciences acquisition and a comparable 4.8% organic gain, but GAAP net income fell 48% as amortization, acquisition costs, a legal reserve charge and higher interest expense swamped the top-line growth.
Returned $2.1B to shareholders via dividends and buybacks in Q2; 410th consecutive quarterly dividend of $0.63/share declared; FY2026 adjusted EPS guidance raised to $5.45-$5.60; comparable sales growth guidance reaffirmed at 6.5-7.5%.
Source and notation
* marks non-cash / ≈ estimated. Source: Abbott Laboratories press release / 10-Q (SEC EDGAR).
Open the chart as a PNG image ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Heads-up
- net income fell 48% y/y in Q2 2026
Most likely because nutrition sales fell 3.1% reported (-3.6% comparable) on lower volumes; interest expense, net spiked to $299M from $50M y/y, reflecting acquisition-related debt; costs grew faster than revenue (intangible amortization* +57% y/y, taxes on earnings +61% y/y, r&d +23% y/y). Based on the Q2 2026 report.
Company filings on SEC EDGAR ↗ABT earnings history: past report dates
| Apr 16, 2026 Thu | 7:36 ambefore market open | Mar 31, 2026 | — | $0.61−20% y/y |
| Jan 22, 2026 Thu | 7:35 ambefore market open | Dec 31, 2025 | — | ≈$1.01−81% y/y |
| Oct 15, 2025 Wed | 7:33 ambefore market open | Sep 30, 2025 | — | $0.94+0% y/y |
| Jul 17, 2025 Thu | 7:34 ambefore market open | Jun 30, 2025 | — | $1.01+36% y/y |
| Apr 16, 2025 Wed | 7:36 ambefore market open | Mar 31, 2025 | — | $0.76+9% y/y |
| Jan 22, 2025 Wed | 7:13 ambefore market open | Dec 31, 2024 | — | ≈$5.26+478% y/y |
| Oct 16, 2024 Wed | 7:37 ambefore market open | Sep 30, 2024 | — | $0.94+15% y/y |
| Jul 18, 2024 Thu | 7:37 ambefore market open | Jun 30, 2024 | — | $0.74−5% y/y |
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Abbott Laboratories: 5-year financials
| 2021 | 7,071 |
| 2020 | 4,495 |
| 2019 | 3,687 |
| 2018 | 2,368 |
| 2017 | 477 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP).
How we calculate
Figures are the annual report lines as filed, no adjustments. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing.
Corporate governance
2/2good
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
More
- Feb 2026Per the 2025 10-K, Abbott has a single share class (Common Shares); declared dividend of $2.40 per share vs. $2.24 a year earlier (+7.1%). sec.gov ↗
- Dec 2025Diluted shares fell 2.1% over 2020–2025; SBC of $0.66B = 1.5% of $44.3B revenue. data.sec.gov ↗
- Apr 2026An 8-K disclosed a settlement of the shareholder derivative suit over infant formula (In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation) — with no payout borne by shareholders. sec.gov ↗
- Feb 2026Legal Proceedings in the 2025 10-K lists no settled suits for misleading investors and no SEC cases; the DOJ is running a product investigation into infant formula. sec.gov ↗
Scoring: 2.0, no deductions: single share class, share count −2% over 5 years, SBC 1.5% of revenue, dividend raised every year; investor suit over infant formula dismissed, derivative suit settled in the company's favor
- Share classes
- Single class: Common Shares (2025 10-K cover); cumulative voting in board elections.
- Dilution
- Diluted shares −2.1% over 2020–2025 (XBRL), SBC 1.5% of revenue.
- Disclosure
- Full US GAAP reporting: 10-K and 10-Q filed on EDGAR on time.
- Dividends
- Dividend raised every year: $2.08 → $2.24 → $2.40 over 2023–2025; quarterly payout raised to $0.63 from 02/2026 (10-K).
- Lawsuits & regulators
- The investor class action over the Sturgis plant was not settled with a payout (dismissed, per media reports) — no deduction; the derivative suit was settled (2026) with a $40M capex commitment and reforms, with the company as beneficiary; the DOJ formula probe is product-related, no deduction.
- Related parties
- Committee approval policy for related-party transactions; no material transactions disclosed in the 2026 proxy.
How the score works · checked as of Sep 2026
Abbott Laboratories (ABT) earnings: FAQ
How does Abbott Laboratories make money?
Abbott Laboratories brought in $12.6 billion of revenue in Q2 2026, up 13.0% year over year. The largest source was Medical Devices: $5.86 billion, or 47% of the total, followed by Diagnostics ($3.09B, 25%) and Nutrition ($2.14B, 17%); other lines add the remaining 12%. Net income for the quarter was $928 million, down 47.8% year over year.
When is ABT's next earnings date?
Abbott Laboratories (ABT) is scheduled to report on Oct 21, 2026, before market open.
What time does ABT report earnings?
Abbott Laboratories is scheduled to report before market open on Oct 21, 2026. Its last results releases were filed before market open, most recently at 7:36 am ET on Jul 16, 2026.
When did ABT last report earnings?
Abbott Laboratories reported Q2 2026 results on Jul 16, 2026.
What is the EPS estimate for ABT's next earnings?
The consensus EPS forecast is $1.43 (8 analysts), vs $1.30 in the same quarter last year.
Where can I find Abbott Laboratories's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to ABT's filings; this page breaks the latest report down in a Sankey chart.
What was ABT's net income in Q2 2026?
Abbott Laboratories reported net income of $928M for Q2 2026 (−47.8% year over year), under US GAAP.
New to earnings reports? Start with how to read an earnings report.
How this page was made: the figures come from the company's own report on SEC EDGAR; the summary and nuances were drafted by our model from that report. Figures checked against the filing on 08/25/2026. How we make the breakdowns · Report an error
More reports: AMGN · Q2 2026 · BMY · Q2 2026 · CI · Q2 2026 · CVS · Q2 2026 · DHR · Q2 2026 · ELV · Q2 2026 · GILD · Q2 2026 · HCA · Q2 2026 · ISRG · Q2 2026 · JNJ · Q2 2026 · all reports